ERBB2 and neoplasm: By binding its target, neratinib prevents the activation of the 4 HER receptors in HER2-positive BC and inhibits downstream pathways, causing G0/G1 cell cycle arrest and thus inhibiting proliferation in tumor cells in vitro and in cells with innate and acquired trastuzumab resistance [56, 57].